Lilly's big AI deal Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 9 January, 2026

sponsored by Decode Chromatin Regulation to Inform Drug Mechanism, Resistance, and Strategy Reliable readouts of transcriptional regulatory mechanisms enable researchers to decode drug mechanism of action, detect emerging resistance, and design mitigation strategies earlier in development. EpiCypher can accelerate your research with industry-validated CUT&RUN, DNA Methylation, and Fiber-seq Services to assess target engagement, transcription factor occupancy, chromatin accessibility, and epigenetic changes. Generate reproducible epigenomic data that informs target biology, MoA, and biomarker strategy. Learn More

SPOTLIGHT Every FDA drug approval in 2025: Number of new treatments dipped during agency upheaval

news Aktis lands biotech's first IPO of 2026, raising $318M for radiopharmaceuticals Enliven’s Phase 1 leukemia pill data look competitive with Novartis and Terns Exclusive: With new AI deal, Eli Lilly and Chai Discovery kick off a 'year of deployment' in pharma Exclusive: Medipost raises $140M to take Korean stem cell therapy into US Speculation builds about a multibillion-dollar takeout of Revolution Medicines Peer Review Viking gets commercial chief while other obesity biotechs sell; Novo's Uli Stilz steps down Gene editing pioneers launch first startup focused on custom CRISPR therapies

Biopharma’s year doesn’t start on January 1. It starts in San Francisco. Join Endpoints for bold conversations with the leaders shaping what's next. Plus, get access to the Endpoints Hub — our premium meeting space just steps from the action. Reserve your in-person or free virtual pass today.

endpoints pharma Watch now: Fewer drugs, more chaos — a year under the new FDA Secretive Rampart Bioscience shuts down after trying to crack non-viral gene therapy Servier launches VC unit focused on European biotech startups Sanofi calls rejection of potential MS blockbuster 'unexpected,' says it saw 'evolving' FDA perspectives 2025's huge FDA staff cuts mostly didn't impact new drug review timelines, analysis finds Exclusive: Illumina hires former head of National Human Genome Research Institute Zepbound added onto Taltz boosted response rates in psoriatic arthritis patients, Lilly reports HHS loses bid to suspend court block on 340B rebate pilot FDA rejects Vanda’s jet lag drug following yearslong dispute and 'long-shot' review

in case you missed it 1. Gene editing startup Tessera to lay off 90 employees, according to document, as it begins first clinical study 2. Exclusive: An MIT trio built some of biotech’s favorite AI models. Now, they're building a business 3. Exclusive: GSK to pay $50M to use Noetik's AI cancer models 4. Obesity biotech Alveus gains $160M for push into MariTide's backyard — and amylins 5. Former Genentech leaders’ protein degrader startup nets $107M